2011
DOI: 10.1016/j.yexmp.2011.06.006
|View full text |Cite
|
Sign up to set email alerts
|

Quantitative evaluation of SPRR3 expression in esophageal squamous cell carcinoma by qPCR and its potential use as a biomarker

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
11
0

Year Published

2012
2012
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 24 publications
(16 citation statements)
references
References 35 publications
5
11
0
Order By: Relevance
“…It has been reported that SPRR3 is overexpressed in several tumor types, and is associated with tumor cell proliferation and invasion. Therefore, SPRR3 could be a potential biomarker and novel therapeutic target [ 45 47 ].…”
Section: Resultsmentioning
confidence: 99%
“…It has been reported that SPRR3 is overexpressed in several tumor types, and is associated with tumor cell proliferation and invasion. Therefore, SPRR3 could be a potential biomarker and novel therapeutic target [ 45 47 ].…”
Section: Resultsmentioning
confidence: 99%
“…Furthermore, SPRR3 has two mRNA splice variants, SPRR3-v1 and -v2. SPRR-v1 is highly expressed in the esophageal mucosa of healthy individuals, whereas SPRR3-v2 expression is higher in the adjacent mucosal tissues in patients with esophageal squamous cell carcinoma [21]. High SPRR3 expression also has been reported in colorectal cancer, breast cancer, and glioblastoma multiforme (the most common primary brain tumor in adults); thus, this protein is a reported candidate biomarker for cancer diagnosis [22][23][24].…”
Section: Discussionmentioning
confidence: 99%
“…Out of the 47 genes, 14 genes showed a significantly increased expression level in cancers than in normal tissues (fold change > 2, p < 10 Table 4 It has been reported that SPRR3 is overexpressed in several tumor types, and is associated with tumor cell proliferation and invasion. Therefore, SPRR3 could be a potential biomarker and novel therapeutic target [45][46][47].…”
Section: Selection Pressures On Cancer-associated Genesmentioning
confidence: 99%